GLP-3 (Reta) also known as Retatrutide is a next-generation research peptide studied for its interaction with multiple receptor pathways, including GLP-1, GIP, and glucagon, within controlled laboratory environments. Its multi-receptor profile has made it a subject of increasing interest in advanced peptide research, particularly in studies focused on complex pathway interactions and metabolic signaling mechanisms.
Unlike single-pathway peptides, retatrutide is designed to engage multiple biological targets simultaneously, offering researchers a more comprehensive model for analyzing peptide-receptor dynamics. This has positioned it as a valuable compound in experimental settings requiring a broader analytical scope and deeper insight into multi-pathway activity.
Retatrutide is supplied as a lyophilized (freeze-dried) powder, ensuring stability during storage and precise handling in laboratory applications. Each batch is produced and handled under controlled conditions to maintain structural integrity and consistency across all vials.
Triple–Receptor Agonist Study
Clinical research on GLP-1, GIP, and glucagon pathways
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
GLP-1 Signaling Overview
Foundational research on metabolic hormone pathways
https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
Retatrutide Clinical Research (GLP-1, GIP, Glucagon)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract
